Skip to content
HowShorted

Aquestive Therapeutics, Inc. short interest in 2020

In 2020, Aquestive Therapeutics, Inc.'s disclosed short interest ran from 2.72% of shares outstanding on 15 Jan 2020 to 4.98% on 31 Dec 2020, a change of +2.26 percentage points. The year's high was 7.23% on 15 Oct 2020 and its low 2.72% on 15 Jan 2020, averaging 5.28% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.22 days on 30 Oct 2020. Full history: Aquestive Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Aquestive Therapeutics, Inc. in 2020

2020 in figures

Start of year
2.72% (15 Jan 2020)
End of year
4.98% (31 Dec 2020)
Change
+2.26 pp
High
7.23% (15 Oct 2020)
Low
2.72% (15 Jan 2020)
Average
5.28%
Highest days to cover
5.22 (30 Oct 2020)
SEC filings marked
9

Every report in 2020

Aquestive Therapeutics, Inc. short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 20202.72%1.00results (8-K)
31 Jan 20204.51%2.04
14 Feb 20205.01%1.64
28 Feb 20206.45%2.98
13 Mar 20205.56%3.1210-K filed, results (8-K)
31 Mar 20205.08%4.61
15 Apr 20204.54%2.96
30 Apr 20204.45%2.52
15 May 20204.13%1.3010-Q filed, results (8-K)
29 May 20203.94%1.00
15 Jun 20204.85%2.11
30 Jun 20205.10%2.10
15 Jul 20205.66%3.66
31 Jul 20206.94%4.39
14 Aug 20205.21%1.8810-Q filed, results (8-K)
31 Aug 20204.56%1.47
15 Sep 20204.46%1.45
30 Sep 20205.58%1.09
15 Oct 20207.23%2.97
30 Oct 20206.87%5.22
13 Nov 20206.32%3.4310-Q filed, results (8-K)
30 Nov 20206.59%4.64
15 Dec 20206.04%4.51
31 Dec 20204.98%1.91

See also: Aquestive Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.